Literature DB >> 16405539

Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma.

Maria Chiara Cantarini1, Franco Trevisani, Antonio Maria Morselli-Labate, Gianludovico Rapaccini, Fabio Farinati, Paolo Del Poggio, Maria Anna Di Nolfo, Luisa Benvegnù, Marco Zoli, Franco Borzio, Mauro Bernardi.   

Abstract

OBJECTIVES: The aim of this study was to assess whether hepatocellular carcinoma occurring in the setting of hepatitis B or C virus infection has different prognosis.
METHODS: We performed a multicentric case-control study comparing 102 pairs of patients affected by hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma. Patients were matched for sex (male/female: 84/18 pairs), age, center, and period of enrollment, underlying chronic liver disease (cirrhosis/chronic hepatitis: 97/5 pairs), Child-Pugh class (A/B/C: 70/25/7 pairs), hepatocellular carcinoma stage (nonadvanced/advanced: 50/52 pairs) and, when possible, modality of cancer diagnosis (75 pairs: 47 during and 28 outside surveillance).
RESULTS: In the whole population, patients with hepatitis B tended to have a poor prognosis than those with hepatitis C (p = 0.160), and this difference became statistically significant among the patients with an advanced hepatocellular carcinoma (p = 0.025). Etiology, Child-Pugh class, gross pathology, and alpha-fetoprotein were the significant independent prognostic factors in the whole population. The distribution of these prognostic factors did not differ between patients with hepatitis B or hepatitis C, both in the whole population and in the subgroup of advanced hepatocellular carcinomas.
CONCLUSION: Hepatitis B virus-related hepatocellular carcinomas have a greater aggressiveness than hepatitis C virus-related tumors, which becomes clinically manifest once they have reached an advanced stage.

Entities:  

Mesh:

Year:  2006        PMID: 16405539     DOI: 10.1111/j.1572-0241.2006.00364.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  32 in total

1.  Efficacy of a community-based participatory and multilevel intervention to enhance hepatitis B virus screening and vaccination in underserved Korean Americans.

Authors:  Grace X Ma; Minsun M Lee; Yin Tan; Alexandra L Hanlon; Ziding Feng; Theresa I Shireman; Joanne Rhee; Zhengyu Wei; Frank Wong; Han Seung Koh; Charles Kim; Whitney York
Journal:  Cancer       Date:  2017-11-13       Impact factor: 6.860

Review 2.  Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis.

Authors:  Jisun Park; Jinhyun Cho; Joo Han Lim; Moon Hee Lee; Jinchul Kim
Journal:  Target Oncol       Date:  2019-08       Impact factor: 4.493

3.  A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery.

Authors:  Wei-Yu Kao; Chien-Wei Su; Gar-Yang Chau; Wing-Yiu Lui; Chew-Wun Wu; Jaw-Ching Wu
Journal:  World J Surg       Date:  2011-04       Impact factor: 3.352

4.  Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Seung In Seo; Hyoung Su Kim; Won Jin Kim; Woon Geon Shin; Doo Jin Kim; Kyung Ho Kim; Myoung Kuk Jang; Jin Heon Lee; Joo Seop Kim; Hak Yang Kim; Dong Joon Kim; Myung Seok Lee; Choong Kee Park
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

Review 5.  Stereotactic body radiation therapy in hepatocellular carcinoma: Optimal treatment strategies based on liver segmentation and functional hepatic reserve.

Authors:  Po-Ming Wang; Na-Na Chung; Wei-Chung Hsu; Feng-Ling Chang; Chin-Jyh Jang; Marta Scorsetti
Journal:  Rep Pract Oncol Radiother       Date:  2015-04-30

6.  Hepatocellular carcinoma: prevention and therapy.

Authors:  Davendra P S Sohal; Weijing Sun
Journal:  Curr Oncol Rep       Date:  2011-06       Impact factor: 5.075

7.  Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma.

Authors:  Andrew Yu-Keat Khor; Ying Toh; John Carson Allen; David Chee-Eng Ng; Yung-Hsiang Kao; Guili Zhu; Su-Pin Choo; Richard Hoau-Gong Lo; Kiang-Hiong Tay; Jin-Yao Teo; Brian Kim-Poh Goh; Mark Christiaan Burgmans; Farah Gillian Irani; Anthony Soon-Whatt Goh; Pierce Kah-Hoe Chow
Journal:  Hepatol Int       Date:  2014-04-05       Impact factor: 6.047

8.  Eastern Asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma.

Authors:  Winnie Yeo; Pei-Jer Chen; Junji Furuse; Kwang-Hyub Han; Chiun Hsu; Ho-Yeong Lim; Hanlim Moon; Shukui Qin; Ee-Min Yeoh; Sheng-Long Ye
Journal:  BMC Cancer       Date:  2010-11-10       Impact factor: 4.430

Review 9.  Systemic Treatment for Advanced Hepatocellular Carcinoma.

Authors:  Mohamed Bouattour; Neil Mehta; Aiwu R He; Emil I Cohen; Jean-Charles Nault
Journal:  Liver Cancer       Date:  2019-03-06       Impact factor: 11.740

Review 10.  Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies.

Authors:  Puneeta Tandon; Guadalupe Garcia-Tsao
Journal:  Liver Int       Date:  2008-12-24       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.